BioCentury
ARTICLE | Clinical News

June 7 Clinical Quick Takes: Takeda discontinues Ninlaro for amyloidosis; plus La Jolla, Innovent and Atara

June 7, 2019 6:35 PM UTC

Takeda discontinues amyloidosis trial
Takeda Pharmaceutical Co. Ltd. (Tokyo:4502; NYSE:TAK) discontinued the Phase III TOURMALINE-AL1 trial to treat relapsed or refractory systemic amyloid light-chain (AL) amyloidosis after Ninlaro ixazomib plus dexamethasone missed the first of two primary endpoints. Ninlaro, an oral proteasome inhibitor, is approved to treat multiple myeloma.

La Jolla's hereditary hemochromatosis therapy efficacious in interim analysis
Among 26 patients in a Phase II trial to treat hereditary hemochromatosis, La Jolla Pharmaceutical Co. (NASDAQ:LJPC) said LJPC-401 reduced transferrin saturation by 42% vs. 6% for placebo (p<0.0001), meeting the study's primary endpoint. The company's shares finished the week at $12.86, up 142% from Wednesday's close of $5.32...